Hydrocortisone Pos Ursapharm Benelux (Hydrocortisone Acetate)

Hydrocortisone Pos Ursapharm Benelux is used in ophthalmology to manage inflammatory conditions of the eye where a topical corticosteroid is indicated. It may be prescribed by eye care professionals for short‑term treatment to reduce swelling, redness, and discomfort.

• Mild to moderate anterior uveitis
• Post‑operative inflammation after cataract or intraocular surgery
• Allergic conjunctivitis with significant inflammatory component
• Episcleritis or superficial keratitis with edema
• Contact lens‑related inflammatory irritation

• Hydrocortisone acetate is a glucocorticoid pro‑drug that, after ocular absorption, is hydrolyzed to active hydrocortisone. The active molecule binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the synthesis of pro‑inflammatory cytokines, reduces phospholipase A2 activity, and stabilizes lysosomal membranes, collectively decreasing vascular permeability, edema, and leukocyte migration in ocular tissues.

Adverse reactions to ocular hydrocortisone acetate are generally local and dose‑related, though systemic absorption can occur with extensive use.

Common

• Transient burning or stinging on instillation
• Temporary blurred vision that resolves within minutes
• Mild conjunctival hyperemia
• Localized itching or dryness
• Eyelid edema
• Foreign body sensation

Serious

• Increased intra‑ocular pressure leading to glaucoma
• Development of cataract with prolonged therapy
• Secondary ocular infection due to immunosuppression
• Corneal ulceration or perforation in susceptible eyes

When prescribing or using Hydrocortisone Pos Ursapharm Benelux, clinicians and patients should observe several safety considerations to minimize risks.

• Avoid use in eyes with active viral, fungal, or tubercular infections.
• Limit duration to the shortest effective period to reduce risk of pressure elevation.
• Monitor intra‑ocular pressure in patients with a history of glaucoma or steroid response.
• Use with caution in diabetic patients, as systemic absorption may affect glucose control.
• Do not apply to the cornea if a corneal ulcer is present.
• Discontinue if signs of secondary infection appear.
• Keep the container sealed; discard after the indicated period after opening.

Hydrocortisone acetate can interact with other ophthalmic or systemic agents, potentially altering efficacy or safety.

Avoid

• Concurrent use of potent topical NSAIDs in the same eye, which may increase corneal toxicity.
• Systemic corticosteroids, as additive immunosuppression can raise infection risk.
• Anticholinergic eye drops that may exacerbate dry‑eye symptoms.

Use with caution

• Beta‑blocker eye drops, because steroid‑induced IOP rise may counteract glaucoma control.
• Antifungal or antiviral ophthalmic preparations, requiring close monitoring for reduced effectiveness.
• Systemic cyclosporine or tacrolimus, where combined immunosuppression may increase infection susceptibility.